Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, according to the New England Journal of Medicine.

Currently, there is only one U.S. government-approved treatment available for fatty liver disease, Rezdiffra (resmetirom), researchers said. It works by activating a thyroid hormone receptor that promotes reduction of fat buildup in the liver.

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.